Loading...
XNAS
MMSI
Market cap5.09bUSD
Oct 08, Last price  
85.25USD
1D
0.19%
1Q
16.08%
Jan 2017
221.70%
Name

Merit Medical Systems Inc

Chart & performance

D1W1MN
XNAS:MMSI chart
P/E
39.62
P/S
3.36
EPS
2.15
Div yield, %
—
Shrs. gr., 5y
1.75%
Rev. gr., 5y
9.46%
Revenues
1.51b
+11.66%
190,674,000207,768,000227,143,000257,462,000296,755,000359,449,000394,288,000449,049,000509,689,000542,149,000603,838,000727,852,000882,753,000994,852,000963,875,0001,074,751,0001,150,981,0001,257,366,0001,356,514,0001,514,730,000
Net income
128m
+6.76%
12,301,00015,588,00020,727,00022,530,00012,460,00023,044,00019,710,00016,570,00022,974,00023,802,00020,121,00027,523,00042,017,0005,451,000-9,843,00048,454,00074,516,00094,411,000120,357,000128,489,000
CFO
297m
+34.68%
19,106,00032,119,00027,967,00030,070,00034,760,00034,015,00046,938,00051,373,00053,325,00069,458,00053,599,00062,727,00086,533,00077,813,000165,270,000147,231,000114,291,000145,151,000220,799,000297,371,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Merit Medical Systems, Inc. (MMSI) is engaged in the design, development, manufacturing, and worldwide commercialization of disposable medical products. These devices are crucial for a broad spectrum of diagnostic, therapeutic, and interventional procedures, primarily within the fields of cardiology, radiology, oncology, critical care, and endoscopy. The company operates through two main divisions: Cardiovascular and Endoscopy. Its extensive product portfolio includes advanced solutions for diagnosing and treating conditions in peripheral vessels and organs, as well as a comprehensive suite of cardiac intervention products. The latter encompasses tools for vascular access, angiography, electrophysiology, cardiac rhythm management, fluid and hemodynamic monitoring, hemostasis, and various interventional therapies for heart-related ailments. Additionally, MMSI provides customized procedural solutions, offering critical care items, disinfection protection systems, specialized syringes, manifold kits, and tailored trays and packs. Their offerings further extend to coated tubes and wires, alongside sophisticated sensor components for microelectromechanical systems (MEMS). The company also features pulmonary products, such as laser-cut tracheobronchial stents with their accompanying over-the-wire and direct visualization delivery systems, and dilation balloons used for endoscopic stricture dilation. Gastroenterology products, as well as essential kits and accessories for endoscopy and bronchoscopy procedures, complete their diverse catalog. Merit Medical Systems sells its products to a wide client base, including hospitals and healthcare professionals (physicians, technicians, and nurses) working in alternative care settings. Distribution channels include a direct sales force, authorized distributors, original equipment manufacturer (OEM) partnerships, and custom procedure tray manufacturers, reaching customers throughout the United States and internationally. Founded in 1987, Merit Medical Systems, Inc. has its corporate headquarters situated in South Jordan, Utah.

Key people

F. Ann Millner
Independent Chairman of the Board · since 2026
Neil Peterson
Chief Operating Officer · since 2022
Michel Voigt
Chief Human Resources Officer · since 2020
Raul Parra
Chief Financial Officer, Treasurer · since 2018
Brian Lloyd
Chief Legal Officer, Corporate Secretary · since 2016
President, Chief Executive Officer, Director · since 2025
Independent Director · since 2020
Stephen Evans
Independent Director · since 2021
David Floyd
Independent Director · since 2020
Thomas Gunderson
Independent Director · since 2017
Laura Kaiser
Independent Director · since 2022
Independent Director · since 2022
Silvia Perez
Independent Director · since 2024
Lynne Ward
Independent Director · since 2019
IPO date
Sep 16, 1954
Employees
6,846
Domiciled in
US
Incorporated in
US
Legal address
C/O UNITED AGENT GROUP INC.
169 W 2710 S CIRCLE
STE 202-A
SAINT GEORGE, UT 84790
US
Headquarters
1600 W MERIT PKWY
SOUTH JORDAN, UT 84095
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT